{
    "ticker": "ONFO",
    "name": "OncoOne, Inc.",
    "description": "OncoOne, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancer. Founded in 2015, OncoOne is dedicated to addressing unmet medical needs in oncology by leveraging its proprietary technology platform, which identifies and targets the unique characteristics of cancer cells. The company\u2019s lead product candidate, OncoOne-001, is a first-in-class treatment designed to target the oncogene that is overexpressed in various types of tumors. OncoOne is committed to advancing its pipeline of drug candidates through clinical trials, with the aim of improving patient outcomes and quality of life. The company operates with a strong emphasis on scientific rigor and collaboration, working alongside leading research institutions and clinical partners to facilitate the development and commercialization of its therapies. By focusing on precision medicine, OncoOne seeks to provide tailored treatment options that are based on the specific genetic and molecular profiles of individual tumors, thereby enhancing the effectiveness of cancer therapies and minimizing side effects. As the company progresses through its clinical trials, it aims to bring transformative solutions to patients battling cancer, reinforcing its commitment to innovation in the biopharmaceutical sector.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boulder, Colorado, USA",
    "founded": "2015",
    "website": "https://www.oncoone.com",
    "ceo": "Dr. Lothar Krinke",
    "social_media": {
        "twitter": "https://twitter.com/OncoOne",
        "linkedin": "https://www.linkedin.com/company/oncoone/"
    },
    "investor_relations": "https://investors.oncoone.com",
    "key_executives": [
        {
            "name": "Dr. Lothar Krinke",
            "position": "CEO"
        },
        {
            "name": "Dr. Christine M. B. H. F. M. van Bockel",
            "position": "CSO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "OncoOne-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "OncoOne, Inc. | Innovative Cancer Therapies",
        "meta_description": "OncoOne, Inc. is dedicated to developing innovative cancer therapies through precision medicine. Learn about our pipeline and commitment to patient care.",
        "keywords": [
            "OncoOne",
            "Biotechnology",
            "Cancer Treatment",
            "Oncology",
            "OncoOne-001"
        ]
    },
    "faq": [
        {
            "question": "What is OncoOne known for?",
            "answer": "OncoOne is known for developing innovative cancer therapies, particularly its lead product candidate OncoOne-001."
        },
        {
            "question": "Who is the CEO of OncoOne?",
            "answer": "Dr. Lothar Krinke is the CEO of OncoOne, Inc."
        },
        {
            "question": "Where is OncoOne headquartered?",
            "answer": "OncoOne is headquartered in Boulder, Colorado, USA."
        },
        {
            "question": "What are OncoOne's main products?",
            "answer": "OncoOne's main product is OncoOne-001, a novel cancer therapy."
        },
        {
            "question": "When was OncoOne founded?",
            "answer": "OncoOne was founded in 2015."
        }
    ],
    "competitors": [
        "CLVS",
        "EXEL",
        "NVS",
        "AMGN"
    ],
    "related_stocks": [
        "PFE",
        "MRNA",
        "GILD",
        "BMY"
    ]
}